DaraDHolderMD

Male Sexual Dysfunction, Stone Disease, Infections & Inflammation

Urologist

Dr. Holder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Wisconsin Hospitals and ClinicsResidency, Urology, 2014 - 2018
New York Presbyterian Hospital (Columbia Campus)Residency, Surgery, 2013 - 2014
Columbia University Vagelos College of Physicians and SurgeonsClass of 2013
University of PennsylvaniaBachelor's, Biochemistry and Health and Societies, Cum Laude with a distinction in Biochemistry, 2004 - 2008

James M. McKiernan MD Prize for Compassionate Care Columbia University, 2013
Honorable Mention, Ferdinand C Valentine Urology Essay Competition New York section of the AUA, 2012
Rudin Scholarship Columbia University, 2008

PubMed

Journal Articles

Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of non-muscle invasive urothelial carcinoma of the bladder after bacillus Calmet...
McKiernan JM, Holder DD, Ghandour RA, Barlow LJ, Ahn JJ, Kates M, Badalato GM, Roychoudhury A, Decastro GJ, Benson MC, J Urol, 1/1/2014
Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology
Lin J, Whalen M, Holder D, Hruby G, Decastro GJ, McKiernan J, Can J Urol, 1/1/2013
High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts
Xia SJ, Holder DD, Pawel BR, Zhang C, Barr FG, American Journal of Pathology, 1/1/2009

Abstracts/Posters

Prognostic Effect of a Re-TURBT prior to neoadjuvant chemotherapy for urothelial carcinoma of the bladder
Dara D. Holder, Josep Gaya, Greg Hruby, Mitchell Benson, Daniel Petrylak, G. Joel DeCastro, James McKiernan, World Congress of Endourology, Istanbul, Turkey, 1/1/2012
Updated Results of the combined phase I/II trial of Intravesical nanoparticle albumin bound paclitaxel in the treatment of BCG refractory non-muscle invasive transitio...
James M. McKiernan, Dara D. Holder, American Urologic Association, Atlanta, GA, 1/1/2012
Identification of a Predictive factor for response to neoadjuvant chemotherapy in urothelial carcinoma
Dara D. Holder, Josep Gaya, G. Joel DeCastro, James M. McKiernan, Eastern Atlantic Student Research Forum, University of Miami, Miami, FL, 1/1/2012
The role of MYCN in Alveolar Rhabdomyosarcoma tumorigenesis
Dara D. Holder, Frederic Barr MD PHD, Department of Biochemistry Senior Research Symposium, University of Pennsylvania, Philadelphia, PA, 1/1/2008
Join now to see all

Lectures

Phase II trial of intravesical nano-particle albumin – bound paclitaxel for the treatment of non-muscle invasive urothelial carcinoma after BCG failure
San Diego, CA - 1/1/2013
Therapeutic effect of a Re-TURBT prior to Neoadjuvant chemotherapy for urothelial carcinoma of the bladder
New York, NY - 1/1/2012
Repeat Transurethral resection prior to neoadjuvant chemotherapy for urothelial carcinoma of the bladder
New York, NY - 1/1/2012
Evaluating Efficacy: “Trends in Breast Cancer staging at the Breast Examination Center of Harlem [BECH] over 13 years”
Memorial Sloan Kettering Cancer Center, New York, NY - 1/1/2009
HIV/AIDS and Assumptions: Case manager’s influence on the dissemination of HIV prevention to their seriously mentally ill clients
Leonard Davis Institute for Health Economics, University of Pennsylvania - 1/1/2007
Join now to see all